Current Research Studies

The Effects of Tirzepatide in Young adults with Prader-Willi Syndrome, Hypothalamic Obesity and General Non-Syndromic Obesity

Tirzepatide

Phase: N/A
Clinicaltrials.gov ID: NCT06901245

What is the goal of the study?

To evaluate the percent change in weight and BMI from baseline during 48 weeks of treatment with tirzepatide in young adults with Prader-Willi Syndrome (PWS), hypothalamic obesity (HO), general non-syndromic obesity (GNSO) and obesity

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Grace Kim
Study Team Member: Barbara Maslaney, [email protected]